{"entity":{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","aka":[],"tldr":"A phase 2 trial of ABSK-011+BSC in hepatocellular carcinoma, run by Abbisko Therapeutics Co, Ltd, now recruiting.","summary":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression is a phase 2 interventional study registered as NCT07327034 by Abbisko Therapeutics Co, Ltd, with 141 participants planned, started 2025-06-13 and due to reach its primary completion in 2027-06-30. Interventions recorded: ABSK-011+BSC and Placebo+BSC.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07327034","url":"https://clinicaltrials.gov/study/NCT07327034"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07327034","phase":"2","setting":"A Randomized, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of ABSK-011 Plus Best Supportive Care (BSC) vs. Placebo Plus BSC in Previously Systemically Treated Advanced or Unresectable Hepatocellular Carcinoma Patients With FGF19 Overexpression","sponsor":"Abbisko Therapeutics Co, Ltd","enrolled":141,"outcomes":[]},"route":"/trials/nct07327034/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}]}}